Vergent plans to use the funding to advance the development of the company’s fluorescent tumor imaging agent VGT-309. Initially, VGT-309 will be used to illuminate lung cancer tumors, according to the Oct. 4 Vergent news release.
Orlando Health Ventures led the funding round. This funding round brings Vergent’s total capital raised to $34 million.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.